Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents

References

• Ansseau M., Darimont P., Lecoq A., et al. Controlled comparison of nefazodone and amitnptyline in major depressive inpatients. Psychopharmacology 1994; 115: 254–60
   PubMedGoogle Scholar
• Armitage R., Rush A.J., Trivedi M., Cain J., Roffwarg H.P. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 1994; 10(2)123–7
   PubMed Web of Science ®Google Scholar
• Bersani G., Pozzi F., Marini S., et al. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatrica Scandinavica 1991; 83: 244–8
   PubMedGoogle Scholar
• Blier P., De Montigny C., Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. Journal of Clinical Psychiatry 1990; 51(4)14–20, Suppl
   PubMedGoogle Scholar
• Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences 1993; 52(12)1023–9
   PubMed Web of Science ®Google Scholar
• Bryant S.G., Hokanson J.A., Brown C.S. A drug utilization review of prescribing patterns for trazodone versus amitripcyline. Journal of Clinical Psychiatry 1990; 51: 27–9, Suppl
   Google Scholar
• Charig E.M., Anderson I.M., Robinson J.M., et al. L-tryptophan and prolactin release: evidence for interaction between 5-HT1 and 5-HT2 receptors. Human Psychopharmacology 1986; 1: 93–7
   Google Scholar
• Charney D.S., Menkes D.B., Heninger G.R. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Archives of General Psychiatry 1981; 38: 1160–80
   PubMed Web of Science ®Google Scholar
• Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114: 559–65
   PubMed Web of Science ®Google Scholar
• D'Amico M.F., Roberts D.L., Robinson D.S., Schwiderskj U.E., Copp J. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacological Bulletin 1990; 26(1)147–50
   PubMed Web of Science ®Google Scholar
• Dubovsky S.L. Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents. Journal of Clinical Psychiatry 1994; 55(2)34–44, Suppl
   Google Scholar
• Eison A.S., Eison M.S., Torrente J.R., Wright R.N., Yocca F.D. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacological Bulletin 1990; 26(3)311–5
   Google Scholar
• Feighner J.P., Pambakian R., Fowler R.C., Boyer W.F., D'Amico M.F. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacological Bulletin 1989; 25(2)219–21
   PubMed Web of Science ®Google Scholar
• Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clinical Neuropharmacology 1993; 16(Suppl 3)S45–50
   Google Scholar
• Fontaine R., Ontiveros A., Elie R., et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. Journal of Clinical Psychiatry 1994; 55: 234–41
   PubMed Web of Science ®Google Scholar
• Haria M., Fitton A., McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs and Aging 1994; 4(4)331–55
   PubMed Web of Science ®Google Scholar
• Katz R.J., Landau P.S., Lott M., et al. Serotonergic (5-HT2) mediation of anxiety—therapeutic effects of serazepine in generalized anxiety disorder. Biological Psychiatry 1993; 34: 41–4
   PubMed Web of Science ®Google Scholar
• Lemberger L., Rowe H., Carmichael R., et al. Fluoxetine, a selective serotonin uptake inhibitor. Clinical Pharmacology and Therapeutics 1978; 421–9
   Google Scholar
• Li Q., Brownfield M.S., Levy A.D., Battaglia G., Cabrera T.M., Van de Kar L.D. Attenuation of hormone responses to the 5-HTIA agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biological Psychiatry 1994; 36: 300–8
   PubMed Web of Science ®Google Scholar
• McElroy S.L., Dessain E.C., Pope H. G., Jr., et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. Journal of Clinical Psychiatry 1991; 52: 411–414
   PubMed Web of Science ®Google Scholar
• Mayol R.F., Cole C.A., Luke G.M., Colson K.L., Kerns E.H. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metabolism and Disposition 1994; 22(2)304–11
   Google Scholar
• Patten S.B. The comparative efficacy of trazodone and imipramine in the treatment of depression. Canadian Medical Association Journal 1992; 146(7)1177–82
   PubMed Web of Science ®Google Scholar
• Peroutka S.J., Sleight A.J., McCarthy B.G., et al. The clinical utility of pharmacological agents that act as serotonin receptors. Journal of Neuropsychiatry 1989; 1: 253–262
   PubMedGoogle Scholar
• Preskorn S.H. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. Journal of Clinical Psychiatry 1993; 54(9, suppl)14–34
   Google Scholar
• Richelson E., Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. Journal of Pharmacology and Experimental Therapeutics 1984; 230: 94
   PubMed Web of Science ®Google Scholar
• Rickels K., Schweizer E., Clary C., Fox I., Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. British Journal of Psychiatry 1994; 164: 802–5
   PubMedGoogle Scholar
• Schildkraut J.J. Catecholamine hypothesis of affective disorder. American Journal of Psychiatry 1965; 122: 509–22
   PubMed Web of Science ®Google Scholar
• Sharpley A.L., Walsh A.E., Cowen P.J. Nefazodone—a novel antidepressant—may increase REM sleep. Biological Psychiatry 1992; 31(10)1070–3
   Google Scholar
• Stahl S.M. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs?. Psychopharmacological Bulletin 1994; 30(1)39–43
   Google Scholar
• Sussman N. The potential benefits of serotonin receptor-specific agents. Journal of Clinical Psychiatry 1994; 55(2)45–51, Suppl
   Google Scholar
• Thompson J. W., Jr., Ware M.R., Blashfield R.K. Psychotropic medication and priapism: a comprehensive review. Journal of Clinical Psychiatry 1990; 51(10)430–3
   PubMed Web of Science ®Google Scholar
• Workman E.A., Short D.D. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. Journal of Clinical Psychiatry 1993; 54(1)5–12
   PubMed Web of Science ®Google Scholar